Prospect:Information for the User
Candesartán/Hidroclorotiazida STADA 16 mg/12,5 mg Tablets EFG
candesartán cilexetilo/hidroclorotiazida
Read this prospect carefully before starting to take this medicine because it contains important information for you.
6.Contents of the pack and additional information
Your medicine is called Candesartán/Hidroclorotiazida Stada. It is used for the treatment of high blood pressure (hypertension) in adult patients. It contains two active ingredients: candesartán cilexetilo and hidroclorotiazida. These work together to lower blood pressure.
Candesartán cilexetilo belongs to a group of medicines called angiotensin II receptor antagonists. It makes blood vessels relax and dilate. This helps to lower blood pressure.
Hidroclorotiazida belongs to a group of medicines called diuretics (tablets to make you urinate). It helps the body to get rid of water and salt, such as sodium, in the urine. This helps to lower blood pressure.
Your doctor may prescribe candesartán/hidroclorotiazida if your blood pressure has not been controlled adequately with candesartán cilexetilo or hidroclorotiazida alone.
Do not take Candesartán/Hidroclorotiazida Stada if:
If you are unsure whether you are in any of these situations, consult your doctor or pharmacist before taking candesartán/hidroclorotiazida.
Warnings and precautions
Consult your doctor, pharmacist, or nurse before starting to take Candesartán/Hidroclorotiazida Stada if:
Your doctor may monitor your kidney function, blood pressure, and electrolyte levels (such as potassium) at regular intervals.
See also the information under the heading “Do not take Candesartán/Hidroclorotiazida Stada if”.
If you are in any of these situations, your doctor may want to see you more frequently and perform some tests.
If you are undergoing surgery, inform your doctor or dentist that you are taking candesartán/hidroclorotiazida. This is because candesartán/hidroclorotiazida, in combination with some anesthetics, may cause excessive lowering of blood pressure.
Candesartán/hidroclorotiazida may cause increased sensitivity of the skin to the sun.
Consult your doctor if you experience abdominal pain, nausea, vomiting, or diarrhea after taking candesartán/hidroclorotiazida. Your doctor will decide whether to continue treatment. Do not stop taking candesartán/hidroclorotiazida on your own.
Children and adolescents
There is no experience with the use of candesartán/hidroclorotiazida in children (under 18 years). Therefore, candesartán/hidroclorotiazida should not be administered to children.
Use in athletes
This medicine contains hydrochlorothiazide, which may produce a positive result in doping control tests
Other medicines and Candesartán/Hidroclorotiazida Stada
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medicine. Candesartán/hidroclorotiazida may affect the way some medicines work, and some medicines may affect candesartán/hidroclorotiazida. If you are using certain medicines, your doctor may need to perform blood tests at regular intervals.
Especially, inform your doctor if you are using any of the following medicines, as your doctor may need to modify your dose and/or take other precautions:
Taking Candesartán/Hidroclorotiazida Stada with food, drinks, and alcohol
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or if you suspect you may be pregnant, consult your doctor or pharmacist before using this medicine.
Pregnancy
Inform your doctor if you are pregnant (or if you suspect you may be). Your doctor will usually advise you to stop taking candesartán/hidroclorotiazida before becoming pregnant or as soon as you know you are pregnant, and will advise you to take another medicine instead of candesartán/hidroclorotiazida. Candesartán/hidroclorotiazida is not recommended at the beginning of pregnancy, and should not be taken after the third month of pregnancy, as it may cause serious harm to your baby if used at this stage.
Breastfeeding
Inform your doctor if you are breastfeeding or plan to start breastfeeding. Candesartán/hidroclorotiazida is not recommended in breastfeeding mothers, and your doctor will choose another treatment for you if you wish to breastfeed, especially if your baby is newborn or premature.
Driving and operating machines
Some people may feel tired or dizzy when taking candesartán/hidroclorotiazida. If this happens, do not drive or operate tools or machines.
Candesartán/Hidroclorotiazida Stada contains lactose and sodium
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medicine.
This medicine contains less than 23 mg of sodium (1 mmol) per tablet; it is essentially “sodium-free”.
Follow exactly the administration instructions for this medication as indicated by your doctor. If in doubt, consult your doctor or pharmacist again.
It is essential to continue taking candesartán/hidroclorotiazida every day.
The recommended dose of candesartán/hidroclorotiazida is one tablet once a day. Swallow the tablet with a glass of water.
Try to take the tablet at the same time every day. This will help you remember to take it.
If you take more Candesartán/Hidroclorotiazida Stada than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 5620420, indicating the medication and the amount taken.
If you forgot to take Candesartán/Hidroclorotiazida Stada
Do not take a double dose to compensate for the missed doses. Simply take the next dose as usual.
If you interrupt treatment with Candesartán/Hidroclorotiazida Stada
If you stop taking candesartán/hidroclorotiazida, your blood pressure may increase again. Therefore, do not stop taking candesartán/hidroclorotiazida before consulting your doctor first.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Stop taking Candesartán/Hidroclorotiazida Stada and go to your doctor immediately if you have any of the following allergic reactions:
Candesartán/hidroclorotiazida may cause a decrease in the number of white blood cells. Your resistance to infections may be reduced and you may notice fatigue, an infection, or fever. If this occurs, inform your doctor. It is possible that your doctor will perform blood tests from time to time to check if candesartán/hidroclorotiazida has had any effect on your blood (agranulocytosis).
Stop taking candesartán/hidroclorotiazida and go to your doctor immediately if you notice the following side effect:
Very rare(may affect up to 1 in 10,000 people):
Other possible side effects include:
Frequent (may affect up to 1 in 10 people)
Rare (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Very rare (may affect up to 1 in 10,000 people)
Frequency not known (the frequency cannot be estimated from the available data)
Reporting of side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this prospectus. You can also report them through the Spanish System for the Pharmacovigilance of Medicines for Human Use. https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Medications should not be disposed of through drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection point at the pharmacy. Ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.
Composition of Candesartán/ Hidroclorotiazida STADA
The active principles are candesartán cilexetilo and hidroclorotiazida. Each tablet contains 16 mg of Candesartán cilexetilo and 12.5 mg of Hidroclorotiazida.
The other components are: Lactose monohydrate, Cornstarch, Hydroxypropylcellulose, Sodium croscarmellose, Magnesium stearate, and Triethyl citrate.
Appearance of the product and contents of the package
Candesartán/ Hidroclorotiazida STADA are white, biconvex tablets, with a notch on one of the faces and marked with CH16 on the same face. The notch serves to fracture and facilitate swallowing but not to divide into equal doses.
Presentation:
Packages of 7, 7x1 (single-dose), 10, 10x1 (single-dose), 14, 14x1 (single-dose), 28, 28x1 (single-dose), 30, 30x1 (single-dose), 50, 50x1 (single-dose), 56, 56x1 (single-dose), 90, 90x1 (single-dose), 98, 98x1 (single-dose), 100, 100x1 (single-dose), 112, 112x1 (single-dose), 126, 126x1 (single-dose), 140, 140x1 (single-dose), 154, 154x1 (single-dose), 168, 168x1 (single-dose), 182, 182x1 (single-dose), 196, 196x1 (single-dose) tablets.
Only some package sizes may be commercially marketed.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization:
STADA Laboratorio, S.L.
Frederic Mompou, 5
08960 Sant Just Desvern (Barcelona) Spain
Responsible for manufacturing:
STADA Arzneimittel AG
Stadastrasse 2 – 18
61118 Bad Vilbel
Germany
Or
STADA Arzneimittel GmbH
Muthgasse 36
1190 Vienna
Austria
Or
Eurogenerics N.V.
Heizel Esplanade B22
1020 Brussels
Belgium
Or
LAMP SAN PROSPERO S.p.A.
Via della Pace, 25/A
41030 San Prospero (Modena)
Italy
Or
Siegfried Malta Ltd.
HHF070 Hal Far Industrial Estate, Hal Far
BBG3000
Malta
Or
Clonmel Healthcare Ltd
Waterford Road, Clonmel, Co.Tipperary
Ireland
Last review date of this prospectus:February 2025
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.